GRAL Stock Summary and Trading Ideas (Grail | NASDAQ:GRAL)

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Grail trades on the NASDAQ stock market under the symbol GRAL.

As of September 25, 2026, GRAL stock price climbed to $126.89 with 1,137,793 million shares trading.

GRAL has a beta of 1.85, meaning it tends to be more sensitive to market movements. GRAL has a correlation of 0.04 to the broad based SPY ETF.

GRAL has a market cap of $5.67 billion. This is considered a Mid Cap stock.

Last quarter Grail reported $43 million in Revenue and -$2.56 earnings per share. This fell short of revenue expectation by $-146,400 and missed earnings estimates by -$.05.

The top ETF exchange traded funds that GRAL belongs to (by Net Assets): IWM, XBI, VTI, IWN, IBB.

GRAL has outperformed the market in the last year with a price return of +162.9% while the SPY ETF gained +18.4%. GRAL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +90.6% and +66.5%, respectively, while the SPY returned +5.3% and +1.2%, respectively.

GRAL support price is $118.98 and resistance is $131.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRAL shares will trade within this expected range on the day.